Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Archbishop Emeritus Desmond Tutu visiting the UFS once again
2012-07-13

Archbishop Emeritus Desmond Tutu
13 July 2012

The University of the Free State (UFS) will once again be honoured by the presence of Archbishop Emeritus Desmond Tutu on Wednesday 18 July 2012.

Dr Tutu will be speaking at our Bloemfontein Campus for the first session of a two-day “In Conversation With …”event that is part of the Global Leadership Summit currently being held on the campus.

This sessions starts at 09:30 at the Centenary Complex. The media is invited to attend this session.

Dr Tutu will be in dialogue with Prof. Mark Solms, Head of the Department of Psychology at the University of Cape Town and owner of the Solms-Delta Wine Estate in Franschhoek.

The theme for this conversation, facilitated by Prof. Pumla Gobodo-Madikizela, will be “Living Reconciliation: Winds of Change in Franschhoek and Transformation at Solms-Delta Wine Estate”. This is based on the transformation introduced by Solms on his farm in the Franschhoek Valley.

Prof. Gobodo-Madikizela is a Senior Research Professor on trauma, forgiveness and reconciliation at the UFS.

As owner of Solms-Delta Wine Estate in Franschhoek, Prof. Solms led an initiative to transform the lives of farm workers on the estate through the Wijn de Caab Trust. This initiative was extended to empower the wider community of farm dwellers when Prof. Solms co-founded the Delta Trust and the Franschhoek Valley Transformation Charter. This organisation aims to break trans-generational cycles of social division and inequality in the valley.

The dialogue with Dr Tutu will highlight the significance of these initiatives as examples of deepening the link between socially responsive scholarship, commitment to social justice and responsible citizenship in contemporary South Africa.

Last year, the UFS awarded Dr Tutu an honorary doctorate in Theology, marking a milestone in the history of the university.

At 12:30, Dr Tutu will visit the Red Square in front of the UFS Main Building, where he will join in the fundraising festivities for the university’s official Nelson Mandela Day event and deliver a short address.

Schools in the vicinity, UFS staff and students and the public are invited to take part in the R5 coin laying ceremony in front of the Main Building.

The money collected at this event will be used to benefit the No Student Hungry (NSH) campaign as well as Bloemfontein Child Welfare.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept